Skip to main content

Olopatadine (Ophthalmic)

Medically reviewed by Last updated on May 5, 2020.


(oh la PAT a deen)

Index Terms

  • Olopatadine HCl
  • Olopatadine Hydrochloride

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Ophthalmic:

Pataday: 0.1% (5 mL) [contains benzalkonium chloride]

Pataday: 0.2% (2.5 mL) [contains benzalkonium chloride, edetate disodium]

Patanol: 0.1% (5 mL [DSC]) [contains benzalkonium chloride]

Pazeo: 0.7% (2.5 mL) [contains benzalkonium chloride]

Generic: 0.1% (5 mL); 0.2% (2.5 mL)

Brand Names: U.S.

  • Pataday [OTC]
  • Patanol [DSC]
  • Pazeo

Pharmacologic Category

  • Histamine H1 Antagonist
  • Histamine H1 Antagonist, Second Generation
  • Piperidine Derivative


Selective histamine H1-antagonist; inhibits release of histamine from mast cells. Inhibits histamine induced effects on conjunctival epithelial cells.


Low systemic absorption


Not extensively metabolized


Urine (60% to 70%, mostly as unchanged drug); feces (17%)

Half-Life Elimination

~3 hours

Protein Binding

~55% (primarily albumin)

Use: Labeled Indications

Allergic conjunctivitis: Treatment of ocular itching associated with allergic conjunctivitis.

OTC labeling (Pataday): Temporary relief of itching and redness of the eye(s) caused by grass, ragweed, pollen, and animal dander and hair.


Patanol: Hypersensitivity to olopatadine hydrochloride or any component of the formulation.

Pataday (Rx), Pazeo: There are no contraindications listed in the manufacturer's labeling.

OTC labeling (Pataday): When used for self-medication, do not use if hypersensitive to olopatadine hydrochloride or any component of the formulation, or to treat contact lens-related irritation.

Canadian labeling (Pataday, Pazeo): Additional contraindications (not in the US labeling): Hypersensitivity to olopatadine or any component of the formulation.

Dosing: Adult

Allergic conjunctivitis: Ophthalmic:

Pataday 0.2% (Rx and OTC), Pataday 0.7% (OTC), Pazeo: Instill 1 drop into each affected eye once daily.

Pataday 0.1% (OTC), Patanol: Instill 1 drop into each affected eye twice daily (allowing 6 to 8 hours between doses).

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Allergic conjunctivitis:

Olopatadine 0.1%: Children ≥2 years and Adolescents: Ophthalmic: Instill 1 drop into affected eye(s) twice daily (allowing 6 to 8 hours between doses).

Olopatadine 0.2%: Children ≥2 years and Adolescents: Ophthalmic: Instill 1 drop into affected eye(s) once daily.

Olopatadine 0.7%: Pazeo: Children ≥2 years and Adolescents: Ophthalmic: Instill 1 drop into affected eye(s) once daily.


Ophthalmic: For topical ophthalmic use only. Wash hands prior to use. Do not touch tip of container to eye. After instilling drops, wait ≥10 minutes before inserting contact lenses. Do not insert contacts if eyes are red. If using other eye drops, wait at least 5 minutes before administering other eye drops.


Store at 2°C to 25°C (36°F to 77°F).

Drug Interactions

There are no known significant interactions.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Central nervous system: Headache (≤5%)

Gastrointestinal: Dysgeusia (2% to 5%), nausea (≤5%)

Infection: Cold symptoms (≤10%)

Neuromuscular & skeletal: Back pain (≤5%), weakness (≤5%)

Ocular: Abnormal sensation in eyes (2% to 5%), blurred vision (2% to 5%), dry eye syndrome (2% to 5%), superficial punctate keratitis (2% to 5%), burning sensation of eyes (≤5%), conjunctivitis (≤5%), eyelid edema (≤5%), eye pain (≤5%), eye pruritus (≤5%), foreign body sensation (≤5%), keratitis (≤5%), stinging of eyes (≤5%), hyperemia

Respiratory: Pharyngitis (≤10%), cough (≤5%), rhinitis (≤5%), sinusitis (≤5%)

Miscellaneous: Flu-like symptoms (≤5%), hypersensitivity (≤5%), infection (≤5%)


Other warnings/precautions:

• Contact lens: Not for use to treat contact lens-related irritation. Solution contains benzalkonium chloride; remove lens prior to administration and wait ≥10 minutes before reinserting. Do not use contact lenses if eyes are red.

• Self-medication (OTC use): Discontinue use and contact health care provider if eye pain or changes in vision occur, redness or irritation of the eye continues, or condition worsens or persists for >3 days. Do not use if solution changes color or becomes cloudy.

Pregnancy Considerations

Olopatadine has minimal systemic absorption following ophthalmic administration. Systemic absorption would be required in order for olopatadine to cross the placenta and reach the fetus.

Patient Education

What is this drug used for?

• It is used to treat eye irritation due to allergies.

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Common cold

• Blurred vision

• Foreign body sensation in eye

• Dry eyes

• Change in taste

• Headache

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Vision changes

• Eye pain

• Severe eye irritation

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.